InSphero Acquires PhenoVista Biosciences to Strengthen 3D Drug Testing Platform
Key Insights
InSphero AG (search), a Swiss leader in 3D in vitro models, has acquired San Diego-based PhenoVista Biosciences (search) to expand its advanced drug testing capabilities.
The acquisition combines InSphero's spheroid-based 3D tissue models with PhenoVista's high-content imaging and phenotypic analysis technologies.
The integrated platform aims to accelerate adoption of human-relevant drug discovery workflows, particularly in oncology (search), fibrosis (search), neuroscience (search), and safety assessment.
Swiss biotechnology company InSphero AG (search) has acquired PhenoVista Biosciences (search), Inc., a San Diego-based contract research organization specializing in high-content imaging and phenotypic assay technologies. The strategic acquisition positions InSphero to deliver more comprehensive drug discovery and toxicology testing solutions by combining 3D microtissue platforms with advanced imaging capabilities.
Strategic Combination of Complementary Technologies
The acquisition integrates PhenoVista's expertise in high-content imaging, cell painting, and phenotypic analysis with InSphero's globally recognized 3D microtissue platforms and AkuraFlow (search)™ microphysiological systems. This combination creates integrated workflows that pair advanced 3D biology with high-content imaging and AI-enabled data analytics to generate richer and more predictive datasets earlier in the drug discovery process.
Founded in 2009 as an ETH Zurich (search) spin-off, InSphero develops spheroid-based models—clusters of cells grown in three dimensions to mimic human tissue more closely than flat cell cultures. These models are designed to produce more reliable data and reduce reliance on animal testing. PhenoVista, established in 2014, has built a strong reputation for delivering high-quality, image-based assay development and screening solutions to pharmaceutical and biotechnology customers.
Expanding Therapeutic Applications
The combined organization expects to create substantial opportunities across key therapeutic and translational research areas including oncology (search), fibrosis (search), neuroscience (search), and safety assessment. PhenoVista's work in high-content imaging, cell painting and functional cellular analysis is expected to strengthen applications in neuroscience and neurotoxicity testing, alongside the existing focus areas.
PhenoVista's diverse repertoire includes working with primary cells, iPSC-derived neurons and glia, and client-engineered lines in various formats. Through the integration, PhenoVista gains access to broader global commercial infrastructure, complementary biological platforms, and expanded operational capabilities.
Regulatory Momentum Supporting Growth
The acquisition comes at a time of accelerating momentum behind New Approach Methodologies (NAMs) in the United States. Recent policy initiatives and guidance from the U.S. Food and Drug Administration (search), along with growing investment support from the National Institutes of Health, are creating a strong foundation for broader adoption of human-relevant in vitro technologies.
"The timing of this acquisition is particularly exciting given the accelerating momentum behind New Approach Methodologies in the United States," said Jan Lichtenberg, CEO and Co-founder of InSphero AG (search). "Together with PhenoVista, we are exceptionally well positioned to support this transition with scalable, industry-ready solutions."
Enhanced Customer Value Proposition
The expansion is expected to enable faster turnaround times, closer customer collaboration, and improved access to advanced NAMs technologies in the rapidly growing in vitro market. Customers will benefit from the ability to combine InSphero's superior robustness, reliability, reproducibility, and scalability with PhenoVista's cutting-edge cell models and high-content imaging technologies.
"Joining forces with InSphero represents a highly exciting opportunity for PhenoVista, our employees, and our customers," said James G. Evans. "Both organizations share a strong commitment to advancing drug discovery through innovative assay technologies, advanced analytics, and artificial intelligence-driven approaches."
The deal follows InSphero's recent acquisition of DOPPL (search) and deepens the company's operational base in the US market, positioning it to better serve the growing demand for predictive in vitro modeling solutions.